Market Research Report
Hemophilia A - Epidemiology - 2030
|Hemophilia A - Epidemiology - 2030|
DelveInsight Business Research LLP
Content info: 120 Pages
Delivery time: 2-10 business days
DelveInsight's Hemophilia A- Epidemiology-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Study Period: 2017-2030.
Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII (FVIII). This clotting factor is a part of the intrinsic pathway of blood coagulation. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male.
The symptoms of Hemophilia A can vary greatly from one person to another, it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.
Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A. Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VII are also approved for the treatment of hemophilia A. In some cases, subjects with hemophilia A may develop 'inhibitors' against the replacement factor VIII. Inhibitors are antibodies, which are specialized proteins created by the body's immune system to combat foreign or invading substances such as toxins or bacteria. The immune system may recognize replacement factor VIII as 'foreign' and create these antibodies (inhibitors), which target and destroy the replacement factor. For inhibitors treatment is mainly dependent on bypassing agents and immne tolerance therapy (ITI).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors] scenario of Hemophilia A in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
DelveInsight's analysts have assessed that the total prevalent population of Hemophilia A in the 7MM was 42,458 in 2017. In addition to this, it was accessed that the total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.
DelveInsight's estimate suggests that the United States witnessed the highest number of cases with Hemophilia A, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 14,200 cases in 2017. Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy. On the other hand, the Spain had the lowest prevalent population of Hemophilia A in 2017. Furthermore, Japan had 5,297 prevalent cases for Hemophilia A in 2017.
It was also observed that Severe Hemophilia A cases are more prominent in comparison to Mild and Moderate. In the United States, observed number of mild cases were 3,195, i.e., 25% of the diagnosed and Treated Hemophilia A patient pool in 2017. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool. Among the Hemophilia A patients, i.e., with or without/Non-Inhibitors, the latter one accounts for a higher number of Hemophilia A cases.